IMMUSE™ Lactococcus lactis

Product formulations featuring three top-branded ingredients to support healthy aging—Cognizin®, Setria®, and IMMUSE®—represent the pinnacle of scientific research and innovation.

Kyowa Hakko USA is thrilled to announce that our groundbreaking product, IMMUSE™ postbiotic for immune health, has been honored as the inaugural recipient of the the Ingredient of the Year: Microbiome Modulation category in the esteemed annual awards by NutraIngredients-USA.

Kyowa Hakko’s IMMUSE™, a research-backed postbiotic, provides immune support for travelers in this new innovative formula, “Well Traveled Immune Activator.

After a resoundingly successful limited-time offering, Glaxon™ has now added Kyowa Hakko’s IMMUSE™ to all SuperGreens Immune formulas. Glaxon™, producer of sports nutrition dietary supplements, launched this summer a SuperGreens Enhanced Immune Edition that, in addition to the power of Glaxon™'s trademarked Supershrooms® Organic Mushroom Blend, included IMMUSE™, a postbiotic that provides immune support at a cellular level - both of which support the immune systems of its customers.

With an impressive background in mining the microbiome for novel therapies, Prof. Hill helped with the definition of a postbiotic as a part of ISAPP.

With a special interest in immune system dysfunction, including autoimmunity, allergy, and the stress-immune connection, Dr. Moday puts IMMUSE™, an award-winning postbiotic, at the forefront of ingredients to look out for in nutritional supplements.

New consumer surveys reveal supplement users prefer branded ingredients 2x over generic ingredients when making purchasing decisions.

Highlighted at the Annual Supply Side West Conference, the Function of Kyowa Hakko’s Novel Postbiotic was recognized as a leader for Immune Health.

The solution offers superior ease of formulation, potential application versatility, and more comprehensive immune support compared to probiotics and other immune health ingredients.

Kirin Holdings Company, Limited (Kirin Holdings) announces that it will expand manufacturing equipment at the iMUSE Health Science Factory (located in Saitama Prefecture, just north of Tokyo) - a manufacturing center for lactic acid bacteria raw material - in order to meet the increasing demand for Kirin's proprietary Lactococcus lactis strain Plasma (L. lactis strain Plasma), the functional ingredient in the popular iMUSE brand of immune maintenance products. The new manufacturing equipment is scheduled to begin operating in 2023, and will double the annual production capacity of L. lactis strain Plasma to approximately 28 tons in 2023.